Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

The cost-effectiveness agency has backed the combination of Braftovi (encorafenib) and Eli Lilly's Erbitux (cetuximab) as a second-line treatment option for BRAF V600E mutated mCRC after an ...

Genfleet’s drug meanwhile was combined with Eli Lilly’s anti-EGFR-antibody Erbitux (cetuximab) in the phase 2 KROCUS study, which enrolled 40 previously untreated KRAS G12C-mutated NSCLC ...

In this trial, patients will be randomized to petosemtamab monotherapy or investigator’s choice of single agent chemotherapy or cetuximab ... if approved. Eli Lilly and Company In January ...

Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, AstraZeneca AZN and AbbVie ... study evaluating Braftovi in combination with cetuximab and mFOLFOX6 in patients with metastatic colorectal ...

In this trial, patients will be randomized to petosemtamab monotherapy or investigator’s choice of single agent chemotherapy or cetuximab. This was detailed ... if approved. Eli Lilly and Company In ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.